 Yumanity Therapeutics Inc NASDAQ: YMTX has agreed to sell its lead clinical-stage product candidate, YTX-7739, and discovery-stage neuroscience candidates to Janssen Pharmaceutica NV, a unit of Johnson Johnson NYSE: JNJ for 26 million. Yumanity plans to. 